Servier to Acquire Day One Biopharma for $2.5 Billion, Offering $21.50 Per Share
summarizeSummary
Servier has announced its intent to acquire Day One Biopharmaceuticals for $21.50 per share, valuing the company's total equity at $2.5 billion. This represents a substantial premium over Day One's current trading price of $12.75. This definitive acquisition follows a period of positive momentum for Day One, including strong Q4 and full-year 2025 financial results and a positive EMA opinion for its lead drug, OJEMDA. The acquisition provides an immediate and significant return for shareholders, fundamentally altering the investment thesis for DAWN. Traders will now focus on the deal's closing process and any potential regulatory approvals.
At the time of this announcement, DAWN was trading at $12.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.64 to $13.20. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Reuters.